What are SGLT2 inhibitors used for?

SGLT2 inhibitors like empagliflozin (Jardiance) and dapagliflozin (Farxiga) were first used to lower blood sugar in type 2 diabetes. They are now used just as much to protect the heart and kidneys: to treat heart failure, to slow chronic kidney disease, and to lower cardiovascular risk. Many of these uses apply to people who do not have diabetes.

Do SGLT2 inhibitors work if you do not have diabetes?

Yes. This is one of the biggest changes in how they are used. In heart failure and chronic kidney disease, large trials showed the same benefit whether or not the person had diabetes, because the heart and kidney protection does not depend on lowering blood sugar. A cardiologist or nephrologist may prescribe one to a non-diabetic patient for this reason.

Can SGLT2 inhibitors help you live longer?

In mice, one of them extended lifespan, in males only. In people, there is no lifespan trial, so the plain answer is that we do not know. What is proven is that these drugs prevent heart and kidney disease and their complications, which is a major contribution to healthy aging even without a lifespan claim.

Which is better, Jardiance or Farxiga?

Both empagliflozin (Jardiance) and dapagliflozin (Farxiga) have strong outcome evidence, and for most purposes they are considered similar in benefit. The choice often comes down to the specific approved use, your other conditions, and what your insurance covers. Your physician can match the specific drug to your situation.

Why did canagliflozin extend lifespan only in male mice?

No one is sure, and it is one of the more intriguing puzzles in the field. In the mouse study, males lived about 14% longer while females gained no lifespan, even though both sexes showed similar improvements in weight and blood sugar. 6 That split tells researchers the life-extending mechanism involves more than the metabolic effect, since that was shared, but something else that differs between the sexes. It is also a caution against assuming the male mouse result applies to women, or to people at all.

What are SGLT2 inhibitors used for?

SGLT2 inhibitors like empagliflozin (Jardiance) and dapagliflozin (Farxiga) were first used to lower blood sugar in type 2 diabetes. They are now used just as much to protect the heart and kidneys: to treat heart failure, to slow chronic kidney disease, and to lower cardiovascular risk. Many of these uses apply to people who do not have diabetes.

Do SGLT2 inhibitors work if you do not have diabetes?

Yes. This is one of the biggest changes in how they are used. In heart failure and chronic kidney disease, large trials showed the same benefit whether or not the person had diabetes, because the heart and kidney protection does not depend on lowering blood sugar. A cardiologist or nephrologist may prescribe one to a non-diabetic patient for this reason.

Can SGLT2 inhibitors help you live longer?

In mice, one of them extended lifespan, in males only. In people, there is no lifespan trial, so the plain answer is that we do not know. What is proven is that these drugs prevent heart and kidney disease and their complications, which is a major contribution to healthy aging even without a lifespan claim.

Which is better, Jardiance or Farxiga?

Both empagliflozin (Jardiance) and dapagliflozin (Farxiga) have strong outcome evidence, and for most purposes they are considered similar in benefit. The choice often comes down to the specific approved use, your other conditions, and what your insurance covers. Your physician can match the specific drug to your situation.

Why did canagliflozin extend lifespan only in male mice?

No one is sure, and it is one of the more intriguing puzzles in the field. In the mouse study, males lived about 14% longer while females gained no lifespan, even though both sexes showed similar improvements in weight and blood sugar. 6 That split tells researchers the life-extending mechanism involves more than the metabolic effect, since that was shared, but something else that differs between the sexes. It is also a caution against assuming the male mouse result applies to women, or to people at all.

SGLT2 Inhibitors (Jardiance, Farxiga): Heart, Kidney, Longevity | Philadelphia

TL;DR30-second take

SGLT2 inhibitors, sold as Jardiance (empagliflozin) and Farxiga (dapagliflozin), started as diabetes pills that make you spill sugar in your urine, but their bigger story is organ protection. In large trials they lowered cardiovascular death, kept people with heart failure out of the hospital, and slowed kidney disease, and they do this even in people without diabetes. They also carry a longevity signal: one of them extended lifespan in male mice. There is no human lifespan trial, so the proven human value is protecting the heart and kidneys rather than extending life. The main cautions are yeast infections and a rare form of diabetic ketoacidosis that can happen at near-normal blood sugar.

TL;DR: SGLT2 inhibitors, including empagliflozin (Jardiance) and dapagliflozin (Farxiga), began as diabetes pills that lower blood sugar by spilling it in the urine. Their far bigger story turned out to be organ protection: in large human trials they lowered cardiovascular death, kept heart failure patients out of the hospital, and slowed kidney disease, even in people without diabetes. They also carry a longevity signal, because one of them extended lifespan in male mice in a rigorous aging program. But there is no human lifespan trial, so the proven human value is protecting the heart and kidneys rather than extending life. The main cautions are genital yeast infections and a rare ketoacidosis that can occur at near-normal blood sugar, so the drug is paused around surgery, illness, and fasting.

What are SGLT2 inhibitors, and how do they work?

SGLT2 inhibitors are a class of drugs that includes empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). SGLT2 stands for sodium-glucose cotransporter 2, a protein in the kidney that reabsorbs glucose back into the blood. These drugs block it, so instead of reclaiming that sugar, you pass some of it in your urine. That is how they were first understood: a way to lower blood sugar by spilling it.

What surprised everyone is that their benefits go far beyond glucose. The heart and kidney protection they provide is only partly explained by lower blood sugar.⁸ They gently reduce fluid volume and blood pressure, ease the workload on the heart, move the heart toward a more efficient fuel, and lower the pressure inside the kidney's filtering units. That web of effects, more than the sugar itself, is what makes them one of the most important drug classes of the past decade.

Why do cardiologists prescribe SGLT2 inhibitors?

The turning point came in 2015, when a trial of empagliflozin in people with diabetes and heart disease reported something diabetes drugs had never shown: fewer deaths. Cardiovascular death dropped by about 38%, and hospital stays for heart failure fell sharply.¹ That result reframed the whole class from sugar-lowering pills to heart medicines.

What came next mattered even more. In heart failure with a weakened pump, dapagliflozin reduced deaths and hospitalizations, and it did so whether or not the person had diabetes.² Then, in heart failure with a preserved pump, a type long resistant to every treatment tried, empagliflozin became one of the first drugs to clearly help.³ Today these drugs are a guideline-recommended foundation of heart failure care, for diabetics and non-diabetics alike.

How do SGLT2 inhibitors protect the kidneys, even without diabetes?

The kidney story runs in parallel. In people with chronic kidney disease, dapagliflozin slowed the loss of kidney function and reduced kidney failure and death, again in people with and without diabetes.⁴ A later trial of empagliflozin in an even broader group of kidney patients confirmed the benefit.⁵

The through-line is the part that changed medicine: these drugs protect the heart and kidneys in people who do not have diabetes at all. That is why a cardiologist or a kidney specialist may prescribe one to someone whose blood sugar is normal. The benefit is about the organs rather than the glucose.

Do SGLT2 inhibitors have a longevity benefit?

This is where the longevity world took notice. In the National Institute on Aging's Interventions Testing Program, the rigorous three-lab mouse study that also flagged acarbose, canagliflozin extended the lifespan of male mice by about 14%.⁶ Females did not gain lifespan, even though their metabolism improved as much as the males', which is a clue that the life-extending effect involves more than lower blood sugar.

That finding drew wide attention, and is also easy to over-read. It is a mouse result, it is male-only, and there is no human lifespan trial of these drugs. So the fair position is this: SGLT2 inhibitors have powerful, proven benefits for the heart and kidneys in people, and a promising but unproven longevity signal that lives, for now, in mice.

How are SGLT2 inhibitors dosed, and what are the side effects?

The common doses are simple: empagliflozin 10 milligrams a day (up to 25 for blood sugar), and dapagliflozin 10 milligrams a day. They are taken once daily, with or without food.

The side effects are mostly manageable, with two that deserve close attention.

Genital yeast infections are the most common, because the sugar in the urine feeds yeast. They are usually easy to treat, and more frequent in women.
Euglycemic diabetic ketoacidosis is rare but serious, and the reason it matters is that it can happen while blood sugar looks near-normal, which can delay recognition.⁷ The risk rises around surgery, prolonged fasting, serious illness, and very low-carbohydrate or ketogenic diets, so the drug is usually paused before planned surgery and during acute illness.
Volume-related effects like lightheadedness or dehydration can occur, since the drug is a mild diuretic; this matters most in older or frail people.
An amputation and fracture signal appeared with canagliflozin in one large trial, though it was not clearly seen with empagliflozin or dapagliflozin, and the related warning was later removed.⁹

None of this makes the class dangerous; it makes it a prescription that belongs with a clinician who knows when to hold it, above all around surgery, illness, and fasting.

Guidance from the Clinic

"SGLT2 inhibitors are one of the few paradigm-changing drug classes of my career, and I do not say that lightly. We went from thinking of them as modest diabetes pills to using them to protect the heart and kidneys in people who never had high blood sugar. When a patient has heart failure, chronic kidney disease, or high cardiovascular risk, this is often one of the highest-value tools I can offer. The longevity signal in mice is intriguing, and I keep an eye on it, but I am careful not to sell it as an anti-aging drug, because that trial in people does not exist. What I will say is that protecting your heart and kidneys is itself one of the surest ways to age well, and on that, the evidence here is as strong as it gets."

Key Takeaways

SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga) began as diabetes drugs that spill sugar in the urine, but their major value is protecting the heart and kidneys.
In large human trials they lowered cardiovascular death, kept heart failure patients out of the hospital, and slowed kidney disease, including in people without diabetes.
The benefit comes from effects beyond glucose, which is why they help patients whose blood sugar is normal.
A longevity signal exists in mice: canagliflozin extended male mouse lifespan by about 14%, with no gain in females and no human lifespan trial.
The main cautions are genital yeast infections and a rare ketoacidosis that can occur at near-normal blood sugar, so the drug is paused around surgery, illness, and fasting.

Acarbose: The Diabetes Drug With a Longevity Signal - the other male-mouse-lifespan glucose drug
Rapamycin for Longevity - a drug studied directly for aging
Metformin for Longevity - the most-studied longevity-adjacent diabetes drug
What Is a Preventive Cardiologist? - the decision layer around heart-protective drugs
Finerenone (Kerendia): Protecting the Kidney and Heart - the nonsteroidal MRA that pairs with SGLT2 inhibitors in diabetic kidney disease
Semaglutide (Ozempic) for Kidney Disease - the GLP-1 pillar of cardio-renal protection, from FLOW
Metabolic Health Overview - where blood sugar fits in the bigger picture
GLP-1 Drugs and Heart Failure (HFpEF) - the other drug class now used in HFpEF, and how it differs

Scientific References

Zinman B, Wanner C, Lachin JM, et al. "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes." New England Journal of Medicine. 2015;373(22):2117-2128.
McMurray JJV, Solomon SD, Inzucchi SE, et al. "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction." New England Journal of Medicine. 2019;381(21):1995-2008.
Anker SD, Butler J, Filippatos G, et al. "Empagliflozin in Heart Failure with a Preserved Ejection Fraction." New England Journal of Medicine. 2021;385(16):1451-1461.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. "Dapagliflozin in Patients with Chronic Kidney Disease." New England Journal of Medicine. 2020;383(15):1436-1446.
The EMPA-KIDNEY Collaborative Group. "Empagliflozin in Patients with Chronic Kidney Disease." New England Journal of Medicine. 2023;388(2):117-127.
Miller RA, Harrison DE, Allison DB, et al. "Canagliflozin extends life span in genetically heterogeneous male but not female mice." JCI Insight. 2020;5(21):e140019.
Rosenstock J, Ferrannini E. "Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors." Diabetes Care. 2015;38(9):1638-1642.
Zelniker TA, Braunwald E. "Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review." Journal of the American College of Cardiology. 2020;75(4):422-434.
Neal B, Perkovic V, Mahaffey KW, et al. "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes." New England Journal of Medicine. 2017;377(7):644-657.

Fishtown Medicine | Metabolism

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

The most common is genital yeast infections, since some sugar leaves in the urine. Less common but more serious is a form of diabetic ketoacidosis that can occur even when blood sugar is near-normal, which is why the drug is paused around surgery, serious illness, and prolonged fasting. Some people get lightheaded from the mild fluid loss. Most people tolerate the class well with awareness of these points.

Deep-Dive Questions

Their heart and kidney effects come from a web of actions beyond glucose. They act as a mild diuretic, lowering fluid volume and easing the pressure the heart works against. They appear to improve the heart's energy efficiency, moving it toward fuels it burns more efficiently. They reduce inflammation and oxidative stress, and inside the kidney they lower the pressure in the filtering units that drives long-term damage. The sum of these is why the benefit shows up even when blood sugar is normal, and why the class works across such different conditions.<sup>8</sup>

No one is sure, and it is one of the more intriguing puzzles in the field. In the mouse study, males lived about 14% longer while females gained no lifespan, even though both sexes showed similar improvements in weight and blood sugar.<sup>6</sup> That split tells researchers the life-extending mechanism involves more than the metabolic effect, since that was shared, but something else that differs between the sexes. It is also a caution against assuming the male mouse result applies to women, or to people at all.

Not based on current evidence. The proven human benefits are in people who have, or are at high risk for, heart failure, kidney disease, or cardiovascular disease. For a healthy person with a normal heart and kidneys, there is no outcome trial showing benefit, the longevity data is mouse-only, and the drug carries meaningful risks like ketoacidosis. The foundations of healthy aging, from fitness to diet to sleep, do far more for a healthy person than a prescription aimed at diseases they do not have. If your heart or kidney risk is elevated, though, that calculus changes, and it becomes a conversation to have with your physician.

They sit in an unusual and strong position. Unlike most compounds discussed for longevity, SGLT2 inhibitors have large human trials proving they prevent disease and death, though from heart and kidney disease specifically rather than aging itself. Alongside acarbose, they share the distinction of extending male mouse lifespan in the rigorous NIA program. Compared with rapamycin or metformin, which are studied for aging but lack this scale of human outcome proof, SGLT2 inhibitors are better thought of as proven organ-protectors with a longevity signal attached, rather than longevity drugs in search of proof.

Ready when you are